Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 6Other solid neoplasm 5Gastrointestinal 4Breast 3Endocrine 2Tumor-Agnostic 1Sarcoma 1Other hematologic neoplasm 1NET 1Lymphoid 1Head & Neck 1Gynecologic 1Dermatologic 1

Conditions

Thyroid cancer, Hurthle cell 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Carcinoma, Medullary 1Adenocarcinoma, Follicular 1

Interventions

Cisplatin 620pembrolizumab 323Radiotherapy 319Cetuximab 275Docetaxel 221Radiotherapy, Intensity-Modulated 210Carboplatin 197Fluorouracil 196Paclitaxel 159Nivolumab 138Gemcitabine 124Magnetic Resonance Spectroscopy 94Radiation 85Drug Therapy 77Capecitabine 76toripalimab 75Surgical Procedures, Operative 62durvalumab 60Biopsy 52Cyclophosphamide 50Chemoradiotherapy 47camrelizumab 46Specimen Handling 46Erlotinib Hydrochloride 46Radiosurgery 45130-nm albumin-bound paclitaxel 44Standard of Care 43tislelizumab 42Platinum 41Bevacizumab 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × motesanib diphosphate × Head & Neck × Clear all
NCT00121628 2013-10-09

A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer

Amgen

Phase 2 Completed
184 enrolled
EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡